SWOG
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- Conditions
- Metastatic Malignant Neoplasm in the LiverPancreatic Neuroendocrine TumorStage I Pancreatic Neuroendocrine Tumor AJCC v8Stage II Pancreatic Neuroendocrine Tumor AJCC v8Stage III Pancreatic Neuroendocrine Tumor AJCC v8
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 141
- Registration Number
- NCT05040360
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm
- Interventions
- Other: Educational InterventionOther: Quality-of-Life AssessmentBehavioral: Patient NavigationOther: Questionnaire Administration
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 331
- Registration Number
- NCT04960787
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
🇺🇸Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder WallInfiltrating Renal Pelvis and Ureter Urothelial CarcinomaStage II Bladder Cancer AJCC v8
- Interventions
- Procedure: Therapeutic Conventional Surgery
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 6
- Registration Number
- NCT04871529
- Locations
- 🇺🇸
NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Illinois CancerCare-Eureka, Eureka, Illinois, United States
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Procedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 2062
- Registration Number
- NCT04871542
- Locations
- 🇺🇸
McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States
🇺🇸McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States
🇺🇸Mary Greeley Medical Center, Ames, Iowa, United States
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8Metastatic HER2 Negative Breast CarcinomaMetastatic Malignant Neoplasm in the Brain
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 44
- Registration Number
- NCT04647916
- Locations
- 🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸Centralia Oncology Clinic, Centralia, Illinois, United States
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Conditions
- Lung AdenocarcinomaLung Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 116
- Registration Number
- NCT04625647
- Locations
- 🇺🇸
Kaiser Permanente - Harbor City, Harbor City, California, United States
🇺🇸Kaiser Permanente-Irvine, Irvine, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Conditions
- Metastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- Procedure: Cytoreductive NephrectomyDrug: Active Comparator
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 364
- Registration Number
- NCT04510597
- Locations
- 🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Kingman Regional Medical Center, Kingman, Arizona, United States
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Conditions
- Acral Lentiginous MelanomaMetastatic Cutaneous MelanomaMetastatic MelanomaMetastatic Mucosal MelanomaClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the BrainPathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 112
- Registration Number
- NCT04511013
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
- Conditions
- Atypical Hyperplasia of the BreastPleomorphic Lobular Breast Carcinoma In SituLobular Breast Carcinoma In Situ
- Interventions
- Behavioral: Cancer Educational MaterialsOther: Questionnaire AdministrationOther: Decision AidOther: Interview
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 412
- Registration Number
- NCT04496739
- Locations
- 🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study of MiRNA 371 in Patients with Germ Cell Tumors
- Conditions
- Germ Cell TumorMetachronous Malignant NeoplasmSeminomaStage I Testicular Cancer AJCC V8Stage IA Testicular Cancer AJCC V8Stage IB Testicular Cancer AJCC V8Stage is Testicular Cancer AJCC V8
- Interventions
- Other: Biomarker AnalysisProcedure: Blood Product Collection
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 956
- Registration Number
- NCT04435756
- Locations
- 🇺🇸
UCI Health Newport -- Birch Street, Newport Beach, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Kingman Regional Medical Center, Kingman, Arizona, United States